Date Title Description PDF
09 Jul 2020 On business and financial situation ROVI informs on the Collaboration with Moderna for Outside the United States Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine Candidate Download

Pages

Date Title Description PDF
20 Dec 2021 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 13 December 2021 and 17 December 2021 Download
17 Dec 2021 On business and financial situation ROVI reports that the CHMP has issued a positive opinion on Okedi® for the treatment for schizophrenia Download
13 Dec 2021 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 6 December 2021 and 10 December 2021 Download
06 Dec 2021 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 29 November 2021 and 3 December 2021 Download
22 Nov 2021 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 15 November 2021 and 19 November 2021 Download

Pages

Date Title Description PDF
05 Jul 2019 R&D: new licenses, patents and registered trademarks ROVI announces completion of the Clinical Trial Program that will support the application for marketing authorization for Doria® for the treatment of schizophrenia. Download
02 Jul 2019 Liquidity contracts and specialists Liquidity contract: transactions conducted in the second quarter of 2019 Download
26 Jun 2019 Información sobre dividendos The Company informs about the dividends payment Download
12 Jun 2019 Convocatorias y acuerdos de Juntas y Asambleas generales ROVI releases the information related to its General Shareholders Meeting Download
08 May 2019 Convocatorias y acuerdos de Juntas y Asambleas generales ROVI releases the information related to its 2019 General Shareholders Meeting Download

Pages